Cargando…
Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
Sodium glucose transporter 2 (SGLT2) inhibitors are a recently developed class of drug that have been approved for use in type 2 diabetes. Their unique extra-pancreatic glucuretic mode of action has encouraged their usage in type 1 diabetes as well. At the same time, reports of pseudo ketoacidosis a...
Autores principales: | Kalra, Sanjay, Sahay, Rakesh, Gupta, Yashdeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481661/ https://www.ncbi.nlm.nih.gov/pubmed/26180770 http://dx.doi.org/10.4103/2230-8210.157859 |
Ejemplares similares
-
Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
por: Kalra, Sanjay, et al.
Publicado: (2015) -
Endocrine hygiene
por: Kalra, Sanjay, et al.
Publicado: (2016) -
Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
por: Kalra, Sanjay, et al.
Publicado: (2016) -
Medication counselling with sodium glucose transporter 2 inhibitor therapy
por: Kalra, Sanjay, et al.
Publicado: (2014) -
Metformin + Sodium-glucose Co-transporter-2 Inhibitor: Salutogenic Lifestyle Mimetics in a Tablet?
por: Kalra, Sanjay, et al.
Publicado: (2018)